source · text/csv
source_cc1be5de85f2427f
sha256 15dda31995570a4dcf0f02076cd1858961a823d1c63cae66b6759fc4da69fb0b
by researka:v2 · 2026-06-03 21:30:37.230083+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "98a3a091-c5b2-412b-a3c6-744963f23cb2",
"researka_submission_id": "a544261c-cc24-42d3-b0b0-eb41e2d34b93",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/98a3a091-c5b2-412b-a3c6-744963f23cb2/sidecars/evidence_table.csv"
}